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Since the routine clinical use of the sentinel lymph node (SLN) procedure, questions have been raised concerning
an increase in the overall percentage of node-positive patients. The goal of our study was to compare the
sensitivity of the SLN procedure and the axillary lymph node dissection (ALND) for the identification of positive
lymph nodes in breast cancer.
The incidence of axillary node metastasis in SLNB and ALND specimens from patients undergoing operative
treatment of a primary breast carcinoma was compared retrospectively.
Logistic regression models were used to analyze the effect of various predictors on the presence of positive lymph
nodes. We constructed a multivariate model including the procedure and these predictors that have shown to be
related to lymph node involvement in univariate analysis. The probability of finding positive lymph nodes was thus
calculated in both groups correcting for relevant predictors of lymph node involvement.
The SLNB group included 830 patients, the ALND group 320. In a multivariate analysis, adjusting for the number of
foci, tumor location in the breast, tumor size, LVI, ER, PR, tumor grade and histological subtype, the probability of
finding positive lymph nodes was higher with SLNB procedure than with an ALND. However, this difference was
not statistically significant (OR 0.7635; CI 0.5334-1.0930, p 0.1404).
For comparable tumors, SLNB procedure is at least as sensitive as ALND for detecting positive lymph nodes.
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The axillary lymph node status is the most important
prognostic factor in patients with early breast cancer. It
is determined by patient and tumor characteristics.
To determine the axillary lymph node status, axillary
lymph node dissection (ALND) has been the standard of
care in patients with invasive breast cancer in order to
provide correct staging of the patient and to obtain good
local control. In recent years, however, sentinel lymph* Correspondence: ann.smeets@uzleuven.be
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ALND and has become the standard treatment for axillary
staging in most patients with clinically node-negative
breast cancer on clinical examination, ultrasound and/or
fine needle aspiration cytology (Lyman et al. 2005). The
SLN procedure has been proven to be a feasible, accurate
and suitable method for the staging of the axilla, while
avoiding the morbidity of an ALND (Hack et al. 1999).
Since its routine clinical use, questions have been raised
concerning the upstaging of a subset of node-negative
patients, ranging from 5%-10% in most studies, and an
increase in the overall percentage of node-positive patients
due to a more detailed pathological examination of the
sentinel lymph node (Tvedskov et al. 2011; Smeets &
Christiaens 2005). On the other hand, the SLN procedurean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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et al. 2006; Cserni et al. 2003) and thus understaging of
these patients. Remarkably, axillary recurrence after a
negative SLN biopsy is much lower than expected and
similar to axillary recurrence after ALND (0-3%) (van der
Ploeg et al. 2008; Veronesi et al. 2010; Fisher et al. 2002).
ALND is unlikely to have a therapeutic benefit for most
patients with breast cancer. The value of ALND, especially
in patients whose nodes are found to be tumor-free, is for
accurate staging. An ALND carries the risk of understaging
due to limited pathological examination of the lymph
nodes, which could lead to inadequate treatment.
The goal of our study was to evaluate the sensitivity of
the SLN procedure and the ALND for the identification
of positive lymph nodes in breast cancer.
We hypothesized that the SLNB procedure would lead to
at least equal detection rate of positive lymph nodes than
an ALND when correction was performed for relevant
predictors. The predictors considered were tumor size,
age, number of foci, location of the tumor in the breast,
tumor grade, lymphovascular invasion (LVI), histologic
subtype, hormone receptor status and Her2.
Patients and methods
Patients
Data were obtained from retrospective review of the
Multidisciplinary Breast Center (MBC) database from the
University Hospitals Leuven (Leuven, Belgium). From 1
January 2007 until 31 December 2009, 1300 patients with
a primary operable cT1-cT2N0 invasive breast carcinoma
underwent resection of the primary tumor and axillary
staging by SLNB and/or ALND. The indications for SLNB
were described in institutional guidelines. In patients with
a positive SLN, a completion ALND was performed. The
local surgical treatment consisted of wide excision followed
by radiotherapy or mastectomy with or without radiother-
apy. In patients with a multifocal tumor, size and location
of the largest focus were used for the analysis.
We excluded patients (i) treated for a local recurrence,
(ii) with a carcinoma in situ, (iii) who received neo-adjuvant
therapy and (iv) with primary metastatic disease.
We evaluated the association between each of the
following variables and lymph node involvement: age at
diagnosis, number of foci, histological tumor grade, tumor
location, tumor size, histological subtype, lymphovascular
invasion (LVI), ER, PR, HER-2 status and the procedure
used for axillary staging (SLNB or ALND). Collection of
the patients' data was approved by the local ethics
committee (University Hospitals Leuven).
Sentinel lymph node localization
The sentinel lymph node (SLN) procedure was performed
by injection of a radioactive (99mTc-labelled nanocolloid)
tracer at the level of the tumor and Patent Blue®retroareolar. The SLNs were removed surgically using a
hand-held gamma-ray detection probe.
Examination of the lymph nodes
SLNs were routinely examined by serial sectioning. Every
300 μm 2 coupes were stained, 1 with routine haematoxylin
and eosin (H&E) and 1 stained immunohistochemically
using cytokeratin. Lymph nodes in an ALND were exam-
ined by H&E staining using 3 sections per node. According
to published guidelines, lymph nodes from lobular breast
cancers, classified as lymph node negative on H&E, were
additionally stained with epithelial markers.
Statistical methods
Logistic regression models are used to analyze the effect
of various predictors on the presence or absence of
positive lymph nodes. Given that women with bilateral
breast tumor appear twice in the data set, generalized
estimating equations (GEE) are used to account for the
association between the two responses from the same
person.
First, we built univariate models for a number of
predictors that were expected to be related to lymph node
involvement. For binary or continuous predictors we
calculated the odds ratio (OR) with its 95% confidence
interval and the p-value. For categorical predictors with
more than two levels we performed an overall test of
difference between the various levels and, in case of
significance, odds ratios for the pairwise comparisons
between the levels. The presence of a non-linear relationship
was evaluated for the continuous variables tumor size,
age, and number of foci using restricted cubic splines. In a
second stage, we built a multivariate model including both
procedures (SLNB or ALND) and those predictors that
were related to lymph node involvement in the univariate
analysis or for which such a relationship has been
suggested in the literature. The probability of finding
positive lymph nodes was thus calculated in both groups
correcting for known predictors of lymph node involve-
ment. Two-tailed p-values were applied and p 0.05 was
considered significant.
All analyses were performed using SAS software, version
9.2 of the SAS System for Windows. Copyright © 2002
SAS Institute Inc. SAS and all other SAS Institute Inc.
product or service names are registered trademarks or
trademarks of SAS Institute Inc., Cary, NC, USA.
Results
A total of 1150 patients met eligibility criteria and formed
the study group; 830 patients in the SLNB group, 320
patients in the ALND group. Patient and tumor character-
istics are described in Table 1. Thirty-three per cent of
patients in the ALND group were lymph node positive,
28% in the SLN procedure group. The percentage of
Table 1 Relationships between the procedure used for
axillary staging and clinicopathological factors
Variable ALND (n = 320) SLNB (n = 830)
n % n %
Mean age (yrs) 59 58
Mean tumor size (mm) 27 18
Number of foci
Unifocal 245 77 762 92
Multifocal 75 23 68 8
Histologic grade
Grade 1 48 15 192 23
Grade 2 149 47 376 45
Grade 3 123 38 262 32
Tumor location
Lateral 169 53 447 54
Medial 75 24 207 25
Overlapping 62 19 151 18
Retroareolar 13 4 25 3
pT
pT1 112 35 557 67
pT2-3 208 65 273 33
pN
pN0 214 67 601 72
pN > =1 106 33 229 28
Histologic subtype
Ductal 251 78 694 84
Other 69 22 136 16
Lymphovascular invasion
Present 71 22 128 15
Absent 246 77 687 83
Unknown 3 1 15 2
Estrogen receptor
Positive 270 84 743 90
Negative 50 16 87 10
Progesteron receptor
Positive 234 73 668 80
Negative 86 27 162 20
HER-2
Positive 31 10 75 9
Negative 289 90 748 91
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biopsy increased from 63% in 2007 to 86% in 2009.
Tumors in the ALND group were larger (mean tumor
size 27 mm versus 18 mm) and more frequently multi-
focal (23% versus 8%). The other characteristics were
similar for both groups.In univariate analysis, the risk of lymph node involve-
ment was increased in the ALND group compared to
that of the SLNB group. However, the difference was not
significant (OR 1.2972; CI 0.9826-1.7125; p 0.0663). Fur-
thermore, the risk was significantly related to the pres-
ence of LVI, increasing tumor size, multifocality,
retroareolar or lateral tumor location in the breast, and
positive hormone receptor status (ER;PR). There was no
significant effect of age, tumor grade, histological subtype
and HER-2 (Table 2).
In a multivariate analysis, adjusting for the number of
foci, tumor location in the breast, tumor size, LVI, ER, PR,
tumor grade and histological subtype, the probability of
finding positive lymph nodes was now higher with SLNB
procedure than with an ALND (Table 3). However,
once more this difference was not statistically significant
(OR 0.7635; CI 0.5334-1.0930, p 0.1404).
Discussion
According to our data, SLNB with focused immuno-
histopathology appears to be at least as sensitive as
ALND with routine lymph node analysis.
The univariate analysis did show a higher probability of
detecting positive lymph nodes with an ALND. However,
this is because the ALND group consists of larger and
more multifocal tumors.
Our study has a few potential limitations. First, it is a
retrospective study. Nowadays, it would be unethical
to randomize patients between ALND and SLN biopsy
because of the morbidity associated with an ALND.
Second, in our study the difference between both proce-
dures in detecting positive lymph nodes was not significant.
It might be that the sample size in our study was too small
to detect small but clinically relevant differences.
Another flaw is that we did not differentiate between
macro- and micrometastases. Several studies have demon-
strated that intensified pathological examination of the
SLNs mainly results in detection of more micrometastases
(Tvedskov et al. 2011; van der Heiden-van der Loo et al.
2006). Patients with axillary lymph nodes containing
micrometastases have a higher disease recurrence and a
10%-20% lower overall survival than patients with tumor-
free axillary nodes (Colleoni et al. 2005; Truong et al.
2010). Thus, more accurate staging is important, even if
the increase in positive nodal status is mainly due to
micrometastases.
The strength of our study is the selection of a homoge-
neous group of patients: we compared both techniques in
patients operated on in recent years and during the same
time period. Additionally, only patients with a cT1-2 N0
tumor were included in the analysis as in the period
2007–2009 only these patients were candidates for a
SLN procedure. Additionally, we corrected for all known
predictors of lymph node involvement.
Table 2 Univariate analysis
Obs Test Odds ratio 95% CI p-value
ALND versus SLNB 1.2972 0.9826-1.7125 0.0663
Age, years 1.0031 0.9929-1.0135 0.5497
Multifocality 1.5431 1.2549-1.8975 <0.0001
Grade (overall effect) 0.4190
grade 1 versus grade 2 0.8072 0.5729-1.1373 0.2209
grade 1 versus grade 3 0.8147 0.5674-1.1697 0.2667
grade 2 versus grade 3 1.0092 0.7566-1.3463 0.9502
Tumor location (overall effect) 0.0027
lateral versus medial 1.3955 1.0131-1.9223 0.0414
lateral versus retroareolar 0.4181 0.2161-0.8091 0.0096
medial versus retroareolar 0.2996 0.1501-0.5979 0.0006
Tumor size, mm 1.0455 1.0331-1.0580 <0.0001
LVI 7.2675 5.2014-10.1545 <0.0001
Ductal carcinoma 0.6305
Lobular carcinoma 0.4873
Estrogen receptor (negative vs positive) 0.5911 0.3824-0.9138 0.0180
Progesteron receptor (negative vs positive) 0.6335 0.4552-0.8816 0.0068
HER-2 (negative vs positve) 0.9869 0.1904-5.1146 0.9875
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techniques in detecting positive lymph nodes found a
stage migration of 4-10% after the introduction of the
SLN biopsy (Vanderveen et al. 2006; Meiers et al.
2013; Maaskant et al. 2009; Feinstein 1985; Giuliano
et al. 1995). Most of these studies included patients
from two different time periods which might imply a
shift in risk factors for having lymph node metastases
over time. It thus becomes more difficult to compare
different time periods (Tvedskov et al. 2011; van der
Heiden-van der Loo et al. 2006; Vanderveen et al.
2006; Maaskant et al. 2009). The only study comparing
both techniques in patients operated on during the
same time period was published by Giulianio in 1995.
They concluded that the SLNB increases the accuracy ofTable 3 Multivariate analysis
Predictor p-value









Lobular carcinoma 0.7765axillary staging in breast cancer and can identify signifi-
cantly more patients with lymph node metastases than
ALND (Giuliano et al. 1995).
In addition to the main findings, we showed that positive
nodal status was mainly related to the presence of LVI,
increasing tumor size and multifocality, which is in
accordance to the literature (Patani et al. 2007; Viale
et al. 2005; Chua et al. 2001). Moreover, we showed
that negative nodal status was significantly related to
medial localization of the tumor in the breast. The
small number of published studies that evaluated the
predictive value of tumor location in the process of
lymph node involvement showed similar findings to our
study (Lohrisch et al. 2000; Bevilacqua et al. 2002).
Reports on the correlation between the hormone recep-
tor status and the presence of lymph node metastases are
controversial (Viale et al. 2005; Bevilacqua et al. 2002).
According to our data, patients with hormone receptor
positive tumors have a higher incidence of lymph node
involvement in univariate analysis but not in multivariate
analysis.
The results of our study are reassuring. There is a
tendency to extend the indications for SLNB to the
majority of patients with clinically node-negative axilla.
Based on our results, a SLN biopsy provides correct
staging while avoiding the morbidity of an ALND. In spite
of this, there are still surgeons with a sceptic attitude to
SLNB procedure. Hopefully, our data can help to persuade
them to routinely implement the SLN biopsy in the
surgical treatment of patients with breast cancer.
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For comparable tumors, SLNB procedure is at least as
sensitive as ALND for detecting positive lymph nodes.
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